{"schema_version":"secwatch.filing_event.v1","accession":"0002023658-25-000034","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.697933+00:00","generated_at":"2026-05-21T19:03:35.855119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bicara Therapeutics Q1 net loss $36.8M; cash $462M; ASCO data update planned","bullets":["Cash and cash equivalents of $462.1M as of March 31, 2025, expected to fund operations into H1 2029.","Net loss of $36.8M in Q1 2025, versus $12.5M in Q1 2024; R&D expenses rose to $34.3M.","Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at ASCO 2025 (June 1).","cSCC monotherapy expansion cohort showed ORR of 30.4% and median PFS of 7.0 months at AACR.","Pivotal Phase 2/3 FORTIFI-HN01 trial enrolling; additional expansion cohorts ongoing or planned."],"urls":{"canonical":"https://secwatch.observer/filing/0002023658-25-000034","json":"https://secwatch.observer/filing/0002023658-25-000034.json","markdown":"https://secwatch.observer/filing/0002023658-25-000034.md","text":"https://secwatch.observer/filing/0002023658-25-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000034/0002023658-25-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000034/bcax-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T19:03:35.855119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}